Mind Cure Health Inc
CNSX:MCUR
Mind Cure Health Inc
Mind Cure Health, Inc. operates as a life sciences company to identify and develop products that enhance mental health and wellness. The company is headquartered in Vancouver, British Columbia and currently employs 14 full-time employees. The company went IPO on 2020-09-21. The firm is engaged in developing digital therapeutics technology and researching psychedelic compounds to support science-backed and evidence-based mental health therapy globally. Its digital therapeutics tool, iSTRYM, is a software application that optimizes the healing journey for both patients and clinicians before, during, and after therapy sessions. Its bioinformatics platform, PsyCollage, helps drive research by identifying priority research programs. The company Desire Project is a clinical research program focused on the treatment of female hypoactive sexual desire disorder (HSDD) with 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. The company is engaged in manufacturing synthetic ibogaine, which provides researchers and clinicians with the resources they need to promote healing related to addiction, migraines, cluster headaches, neuropathic pain, treatment-resistant mood disorders, and more.
Mind Cure Health, Inc. operates as a life sciences company to identify and develop products that enhance mental health and wellness. The company is headquartered in Vancouver, British Columbia and currently employs 14 full-time employees. The company went IPO on 2020-09-21. The firm is engaged in developing digital therapeutics technology and researching psychedelic compounds to support science-backed and evidence-based mental health therapy globally. Its digital therapeutics tool, iSTRYM, is a software application that optimizes the healing journey for both patients and clinicians before, during, and after therapy sessions. Its bioinformatics platform, PsyCollage, helps drive research by identifying priority research programs. The company Desire Project is a clinical research program focused on the treatment of female hypoactive sexual desire disorder (HSDD) with 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. The company is engaged in manufacturing synthetic ibogaine, which provides researchers and clinicians with the resources they need to promote healing related to addiction, migraines, cluster headaches, neuropathic pain, treatment-resistant mood disorders, and more.
